Access to treatments for children with SMA returned to the center of healthcare debate following the public gratitude expressed by the Foundation for the Care, Union and Respect of Patients with Spinal Muscular Atrophy, Cúrame RD, to the Ministry of Public Health and Minister Víctor Atallah for their efforts to guarantee medications for minors diagnosed with this disease.
The organization highlighted this step as a relief for families facing a rare, progressive, and high-cost neuromuscular condition, where the speed of medical response is often decisive. The case once again brings access to treatments for children with SMA to the forefront in the Dominican Republic, where the availability of specialized therapies can define the functional and respiratory prognosis of patients.
Cúrame RD’s announcement coincides with a regional context in which several health systems have begun expanding coverage for therapies for spinal muscular atrophy. In Spain, for example, the public system included gene therapy for certain pediatric patients with type 1 and pre-symptomatic SMA, with an estimated benefit for about 30 children per year. This reference shows that the coverage debate is not exclusive to the country, but part of a broader discussion on rare diseases and high-cost medications.
In the Dominican Republic, Public Health’s gesture aims to sustain the supply of drugs within public programs, a measure that can reduce economic barriers for families. For a pathology where early treatment is key, access to treatments for children with SMA is often as important as the diagnosis itself.
Spinal Muscular Atrophy: why time matters
Spinal muscular atrophy is a rare genetic disease that affects motor neurons and causes progressive loss of muscle strength. Available international treatments include disease-modifying therapies and gene replacement therapies, in addition to supportive care such as rehabilitation, respiratory assistance, and nutritional support.
Pediatric health specialists warn that early intervention improves the chances of preserving motor functions and avoiding severe complications. Therefore, every advance in access to treatments for children with SMA has a direct impact on patients’ quality of life and the economic burden on their households.
Dominican Republic and high-cost medications
The case also reopens the discussion on the sustainability of the high-cost medication program, a sensitive piece of the Dominican health system. When it comes to rare diseases like spinal muscular atrophy, the continuity of treatment is as relevant as its initial approval. If the supply fails, the clinical benefit rapidly weakens.
Cúrame RD’s assessment suggests that there were concrete advances in the access pathway, although the central challenge remains maintaining supply and ensuring that access to treatments for children with SMA does not depend on lengthy procedures or families’ ability to pay.
For affected families, the announcement represents a positive sign; for the healthcare system, a reminder that access to treatments for children with SMA requires continuity, medical supervision, and a stable public policy that sustains long-term care.
